Klin Padiatr 2016; 228 - A2
DOI: 10.1055/s-0036-1593549

Three-dimensional tumor cell growth models in vivo drug resistance mechanisms

C Bingel 1, E Koeneke 1, A Bittmann 1, M Sill 2, I Rettig 1, 3, J Ridinger 1, U Fernekorn 4, F Weise 4, A Schober 4, O Witt 1, 5, I Oehme 1
  • 1Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), INF 280, D-69120 Heidelberg, Germany and German Consortium for Translational Cancer Research (DKTK)
  • 2Department of Biostatistics, Medical Biostatistics, German Cancer Research Center, Heidelberg, Germany
  • 3current address: Roche Diagnostics GmbH, Mannheim, Germany
  • 4Department of Nano-Biosystem Technology, Technische Universität Ilmenau, Germany
  • 5Center for Individualized Pediatric Oncology (ZIPO) and Brain Tumors, Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany

The success rates for investigational cancer drugs in clinical development are poor, reflecting the current limitations of preclinical models in recapitulating relevant (patho-)physiological mechanisms of drug resistance, including autophagy. Recently, three-dimensional (3D) growth cultures have been introduced for preclinical drug testing to improve the lack of correlation between monolayer cell cultures and human tumors. Besides 3D growth, it is also important to simulate shear stress, compound flux and removal of metabolites, e.g. via bioreactor systems, through which culture medium is constantly pumped at a flow rate reflecting physiological conditions. Here, we evaluated the effect of 3D growth on several hallmarks of cancer. Three-dimensionally grown neuroblastoma cell lines slowed down proliferation, escaped drug-induced cell death and activated macroautophagy, a recycling pathway often activated by highly proliferative tumors to cope with metabolic stress. Cell culture settings employing more tumor-like models that reflect in vivo resistance mechanisms are of high importance to improve preclinical drug testing, and thereby have great potential to reduce failure rates in drug development.